In 2010, the refractive market remained under pressure in the US and other wealthy nations due to weakened economic conditions, but growing demand in emerging economies more than offset these declines.
Demand for PC-IOLs and other special purpose IOLs drove growth in the IOL industry during 2010.
2010 saw rapid growth in the number of intravitreal injections, but the soaring volume magnified questions about the risks, the costs, and the sustainability of the trend.
In 2010, seven ophthalmic devices achieved FDA regulatory approval and four important 510(k) clearances were granted.
The FDA approved seven ophthalmic drugs for commercialization in the US.
Eleven ophthalmic firms developing products received venture-capital infusions during 2010.
This month's news briefs include news from Alimera Sciences, Alcon, Novartis, Bausch & Lomb, TrueVision 3D Surgical, Advanced Cell Technology, Inc., and New Leaf Venture Partners.
You are not currently logged in.
©2017 Market Scope
Lost your Password